Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.16 Bil Enterprise Value: 9.58 Bil PE Ratio: 106.36 PB Ratio: 2.73 GF Score: 85/100

Qiagen NV at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 03:15PM GMT
Release Date Price: €44.35 (-0.62%)
Luke England Sergott
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everybody. Luke Sergott from Barclays to cover life sciences tools and diagnostics. With me I have the pleasure of meeting John Gilardi, IR and Roland Sackers, CFO of Qiagen. I guess, to kick it off, just kind of go over the high, real high points of the quarter. What you guys are seeing from a demand perspective and then how that's really progressing versus what you guys were expecting?

Roland Sackers
Qiagen N.V. - CFO, MD & Member of Management Board

Sure. First of all, thanks for having us, and thanks for organizing, nice weather, we clearly deserve that. Yes, as you all know, we clearly finished the year '22 quite strong, not only the year, but also particularly in the fourth quarter, had a strong finish, particularly on the non-COVID growth rate, overall good growth rate. I think we were very pleased that all our [platforms] delivered on what we were expecting and adding to the market. And I know that some investors clearly had some concern about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot